

## Special Issue

# The Role of Immunotherapy in Hematological Malignancies Volume II

### Message from the Guest Editor

Hematological malignancies have been the target of immunotherapy since the advent of allogeneic stem cell transplantation, which has shown for the first time the pros and cons of boosting immune responses against tumor cells and the surrounding tissues. Allogeneic donor lymphocyte infusions have proven that it is possible to further boost allo-immune responses to re-attain remissions when the previous tumor immune surveillance has been somewhat lost. Moving from the experience with leukemias, tumor immunotherapy has recently been enriched with the introduction of different therapeutics that rely on potentiating and/or refueling immunity (checkpoint inhibitors, moAbs, and bispecific antibodies) up to the design of engineered T cells that are empowered to recognize tumor antigens through chimeric receptors (CAR-T). Indeed, hematological malignancies represent an ideal target for such approaches due to the direct access to the tumor bed by immune cells. However, a main limitation is represented by the tumor driven immune-suppressive microenvironment, which can turn off immune responses.

### Guest Editor

Prof. Dr. Marco Rossi

Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy

### Deadline for manuscript submissions

closed (15 December 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/164670](https://mdpi.com/si/164670)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)